Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för leucettine L41. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

12 träffar

Bibliografisk träff 2023-05-17

DYRK1A inhibitors leucettines and TGF-β inhibitor additively stimulate insulin production in beta cells, organoids, and isolated mouse islets.

Pucelik B, Barzowska A, Czarna A.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0285208

Bibliografisk träff 2022-01-01

Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats.

Souchet B, Audrain M, Gu Y, Lindberg MF, Orefice NS, Rey E, Cartier N, Janel N, Meijer L, Braudeau J.

J Prev Alzheimers Dis · research support, non-u.s. gov't; journal article · DOI 10.14283/jpad.2022.18

Bibliografisk träff 2021-06-04

A novel inhibitor rescues cerebellar defects in a zebrafish model of Down syndrome-associated kinase Dyrk1A overexpression.

Buchberger A, Schepergerdes L, Flaßhoff M, Kunick C, Köster RW.

J Biol Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.jbc.2021.100853

Bibliografisk träff 2019-12-17

Biological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4-<i>f</i>]quinazolin-9(8<i>H</i>)-one, a Promising Inhibitor of DYRK1A.

Fruit C, Couly F, Bhansali R, Rammohan M, Lindberg MF, Crispino JD, Meijer L, Besson T.

Pharmaceuticals (Basel) · research-article; journal article · DOI 10.3390/ph12040185

Bibliografisk träff 2019-03-18

Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice.

Souchet B, Audrain M, Billard JM, Dairou J, Fol R, Orefice NS, Tada S, Gu Y, Dufayet-Chaffaud G, Limanton E, Carreaux F, Bazureau JP, Alves S, Meijer L, Janel N, Braudeau J, Cartier N.

Acta Neuropathol Commun · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s40478-019-0678-6

Bibliografisk träff 2018-09-27

Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.

Nguyen TL, Duchon A, Manousopoulou A, Loaëc N, Villiers B, Pani G, Karatas M, Mechling AE, Harsan LA, Limanton E, Bazureau JP, Carreaux F, Garbis SD, Meijer L, Herault Y.

Dis Model Mech · research support, non-u.s. gov't; research-article; journal article · DOI 10.1242/dmm.035634

Bibliografisk träff 2015-04-10

Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.

Naert G, Ferré V, Meunier J, Keller E, Malmström S, Givalois L, Carreaux F, Bazureau JP, Maurice T.

Eur Neuropsychopharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.euroneuro.2015.03.018

Bibliografisk träff 2014-09-26

Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II.

Foucourt A, Hédou D, Dubouilh-Benard C, Girard A, Taverne T, Casagrande AS, Désiré L, Leblond B, Besson T.

Molecules · research support, non-u.s. gov't; research-article; journal article · DOI 10.3390/molecules191015411

Bibliografisk träff 2013-12-23

cdc-like/dual-specificity tyrosine phosphorylation-regulated kinases inhibitor leucettine L41 induces mTOR-dependent autophagy: implication for Alzheimer's disease.

Fant X, Durieu E, Chicanne G, Payrastre B, Sbrissa D, Shisheva A, Limanton E, Carreaux F, Bazureau JP, Meijer L.

Mol Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1124/mol.113.090837

Bibliografisk träff 2013-02-06

Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines.

Burgy G, Tahtouh T, Durieu E, Foll-Josselin B, Limanton E, Meijer L, Carreaux F, Bazureau JP.

Eur J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejmech.2013.01.035

Bibliografisk träff 2012-10-08

Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.

Tahtouh T, Elkins JM, Filippakopoulos P, Soundararajan M, Burgy G, Durieu E, Cochet C, Schmid RS, Lo DC, Delhommel F, Oberholzer AE, Pearl LH, Carreaux F, Bazureau JP, Knapp S, Meijer L.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm301034u

Bibliografisk träff 2011-05-26

Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.

Debdab M, Carreaux F, Renault S, Soundararajan M, Fedorov O, Filippakopoulos P, Lozach O, Babault L, Tahtouh T, Baratte B, Ogawa Y, Hagiwara M, Eisenreich A, Eisenreich A, Rauch U, Knapp S, Meijer L, Bazureau JP.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/jm200274d